MYO / Myomo, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Myomo, Inc. (Exact name of the registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Myomo, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-38109 47-0944526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 45 Blue Sky Dr., Suite 101, Burlington, Massachusetts 01803 (Address of principal e

Conflict Minerals Report of Myomo, Inc. For the Year Ended December 31, 2025

Exhibit 1.01 Conflict Minerals Report of Myomo, Inc. For the Year Ended December 31, 2025 Introduction This is the Conflict Minerals Report (the “CMR”) of Myomo, Inc. (the “Company,” “we” or “us” or “our”) for the reporting period from January 1, 2025 to December 31, 2025 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule req

ARS

2025 Annual ReportMyomo Inc. www.myomo.com 2 ToMyFellowShareholders: While we grew revenue 26% to $40.9 million in 2025 and delivered a record 750 MyoPro devices to patients, our growth was constrained by several unexpected challenges. At the beginning of the year, changes to Facebook’s digital advertising policies limited our ability to target individuals based on health-related data, increasing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1

# # #

Exhibit 99.1 Myomo Appoints Joseph M. Manko to its Board of Directors BURLINGTON, MA. (May 13, 2026) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Joseph M. (“Joe”) Manko Jr. as a director effective May

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2026 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 Myomo, Inc. (Exact Na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Empl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO,

Myomo Reports First Quarter 2026 Financial and Operating Results Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources MyoPro® orders received during the quarter were up 12% year-over-year Expanded gross margin, lo

Exhibit 99.1 Myomo Reports First Quarter 2026 Financial and Operating Results Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources MyoPro® orders received during the quarter were up 12% year-over-year Expanded gross margin, lower operating expenses and narrowed net loss Conference call begins at 4:30pm Eastern time today BURLINGTON, Mass. (May 7, 2026) – Myomo,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1

m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

Table of Contents m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2026 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number)

# # #

Exhibit 99.1 Myomo Appoints William J Febbo to its Board of Directors BURLINGTON, MA. (April 16, 2026) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of William “Will” Febbo as a director effective April 14

As filed with the U.S. Securities and Exchange Commission on March 9, 2026

S-8 As filed with the U.S. Securities and Exchange Commission on March 9, 2026 Registration No. 333-    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MYOMO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-0944526 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. E

Myomo, Inc. COMPENSATION RECOVERY POLICY Adopted as of September 13, 2023

Exhibit 97.1 Myomo, Inc. COMPENSATION RECOVERY POLICY Adopted as of September 13, 2023 Myomo, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and former Executive Officers

Myomo, Inc. List of Subsidiaries

Exhibit 21.1 Myomo, Inc. List of Subsidiaries Subsidiary Legal Name Employer ID Number % Owned State/Country Incorporated Myomo Europe GmbH NA 100% Germany

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 MYOMO, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share, 2018 Stock Option and Incentive Plan Other 1,538,854 $ 0.7405 $ 1,139,521.37 0

MYOMO, INC. AMENDED AND RESTATED Insider Trading POLICY

Exhibit 19.1 MYOMO, INC. AMENDED AND RESTATED Insider Trading POLICY Myomo, Inc. (the “Company”) has adopted the following policy and procedures for securities trading by Company directors and employees (our “Insider Trading Policy”). Our Insider Trading Policy is intended to prevent the misuse of material nonpublic information, insider trading in securities, and the severe consequences associated

Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and ord

Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conf

m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Nothing contained in this Agreement, any other agreement with the Company, or any Company policy limits the Executive’s ability, with or without notice to the Company, to: (i) file a charge or complaint with any federal, state or local governmental a

Exhibit 10.10 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (the “Amendment”) is made as of February 21, 2024, and amends the Employment Agreement dated April 22, 2021 between Myomo, a Delaware corporation (the “Company”), and Micah Mitchell (the “Executive”) (such Agreement, the “Employment Agreement”). NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, a

EMPLOYMENT AGREEMENT

Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is between Myomo, Inc. (“Myomo” or the “Company”), a Delaware corporation with offices at 137 Portland St., 4th Floor, Boston, MA 02114, and Paul R. Gudonis, an individual (“Executive”) residing at 56 Masconomo St., Manchester, MA 01944, is made as of the date of the last signature on the signature pages hereto and upon

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 Myomo, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2025 Myomo, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOM

LOAN AND SECURITY AGREEMENT MYOMO, INC., AVENUE CAPITAL MANAGEMENT II, L.P., AVENUE VENTURE OPPORTUNITIES FUND II, L.P., LOAN AND SECURITY AGREEMENT ARTICLE 1 - INTERPRETATION ARTICLE 2 - THE COMMITMENT AND LOANS ARTICLE 3 - REPRESENTATIONS AND WARRA

Exhibit 10.1 LOAN AND SECURITY AGREEMENT Dated as of November 4, 2025 among MYOMO, INC., a Delaware corporation (“Borrower”) and AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership (as administrative agent and collateral agent (in such capacity “Agent”) and AVENUE VENTURE OPPORTUNITIES FUND II, L.P., a Delaware limited partnership, (“Avenue 2”), as a lender (in such capacity, togeth

Exhibit 10.2 SUPPLEMENT MYOMO, INC. AVENUE CAPITAL MANAGEMENT II, L.P., AVENUE VENTURE OPPORTUNITIES FUND, L.P. II, BORROWER: EXHIBIT “B” EXHIBIT “C”

CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECASUE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

WARRANT TO PURCHASE SHARES OF COMMON STOCK OF MYOMO, INC. (Void after November 4, 2030)

Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF (A) SUCH REGISTRATION, (B) AN OPI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 Myomo, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Myomo Reports Third Quarter 2025 Financial and Operating Results Revenue of $10.1 million 229 authorizations and orders, highest number this year Reiterates full year revenue guidance of $40 million to $42 million Conference call begins today at 4:30

Exhibit 99.1 Myomo Reports Third Quarter 2025 Financial and Operating Results Revenue of $10.1 million 229 authorizations and orders, highest number this year Reiterates full year revenue guidance of $40 million to $42 million Conference call begins today at 4:30pm Eastern time BURLINGTON, Mass. (November 10, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO,

Myomo Reports Second Quarter 2025 Financial and Operating Results Revenue of $9.7 million 816 patients added to the MyoPro pipeline Updates 2025 revenue guidance Conference call begins today at 4:30pm Eastern time

Exhibit 99.1 Myomo Reports Second Quarter 2025 Financial and Operating Results Revenue of $9.7 million 816 patients added to the MyoPro pipeline Updates 2025 revenue guidance Conference call begins today at 4:30pm Eastern time BURLINGTON, Mass. (August 11, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Myomo, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em

Myomo Provides Highlights of Today’s Investor & Analyst Day Event Senior executives to provide an in-depth review of the Company’s business model and discuss long-range aspirational financial metrics

Exhibit 99.1 Myomo Provides Highlights of Today’s Investor & Analyst Day Event Senior executives to provide an in-depth review of the Company’s business model and discuss long-range aspirational financial metrics BURLINGTON, Mass. (June 18, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those sufferin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 MYOMO, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Exhibit 1.01 — Conflict Minerals Report of Myomo, Inc. for the year ended December 31, 2024, as required by Items 1.01 and 1.02 of this Form SD.

Exhibit 1.01 Conflict Minerals Report of Myomo, Inc. For the Year Ended December 31, 2024 Introduction This is the Conflict Minerals Report (the “CMR”) of Myomo, Inc. (the “Company,” “we” or “us” or “our”) for the reporting period from January 1, 2024 to December 31, 2024 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule req

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Myomo, Inc. (Exact name of the registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Myomo, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-38109 47-0944526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 45 Blue Sky Dr., Suite 101, Burlington, Massachusetts 01803 (Address of principal e

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Empl

Myomo Reports First Quarter 2025 Financial and Operating Results Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held toda

Exhibit 99.1 Myomo Reports First Quarter 2025 Financial and Operating Results Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time BURLINGTON, Mass. (May 7, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

ARS

my own motion 2024 Annual Report 2024 Letter to Shareholders -A Year of Transformation, Growth and Impact Dear Fellow Shareholders, 2024 was a pivotal year for Myomo.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1

Letter from Marcum LLP, dated April 9, 2025.

Exhibit 16.1 April 9, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Myomo, Inc. under Item 4.01 of its Form 8-K dated April 4, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Myomo, Inc. contained therein. Very truly yo

Regulation FD Disclosure, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em

Myomo Announces Upcoming Changes to its Board of Directors

Exhibit 99.1 Myomo Announces Upcoming Changes to its Board of Directors BURLINGTON, Mass. (April 10, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that directors Amy Knapp and Yitzchak Jacobovitz have informed the b

Filing Fee Table.

Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Myomo, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per

As filed with the U.S. Securities and Exchange Commission on March 10, 2025

As filed with the U.S. Securities and Exchange Commission on March 10, 2025 Registration No. 333-     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MYOMO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-0944526 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Emp

Amendment to Employment Agreement dated February 21, 2024 by and between Myomo, Inc. and Micah Mitchell.

Exhibit 10.10 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (the “Amendment”) is made as of February 21, 2024, and amends the Employment Agreement dated April 22, 2021 between Myomo, a Delaware corporation (the “Company”), and Micah Mitchell (the “Executive”) (such Agreement, the “Employment Agreement”). NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, a

List of Subsidiaries

Exhibit 21.1 Myomo, Inc. List of Subsidiaries Subsidiary Legal Name Employer ID Number % Owned State/Country Incorporated Myomo Europe GmbH NA 100% Germany

Employment Agreement dated December 13, 2023 by and between the Company and Paul R Gudonis

Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is between Myomo, Inc. (“Myomo” or the “Company”), a Delaware corporation with offices at 137 Portland St., 4th Floor, Boston, MA 02114, and Paul R. Gudonis, an individual (“Executive”) residing at 56 Masconomo St., Manchester, MA 01944, is made as of the date of the last signature on the signature pages hereto and upon

Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million Generated first-ever positive quarterly cash flow from operations Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline Introduces 2

Exhibit 99.1 Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million Generated first-ever positive quarterly cash flow from operations Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline Introduces 2025 revenue guidance of $50 million to $53 million Conference call being held today at 4:30pm Eastern time BURLINGTON, Mass. (March 10, 2

m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Compensation Recovery Policy (Incorporated by reference to Exhibit 97.1 contained in the Registrant's Form 10-K filed on March 8, 2024).

Exhibit 97.1 Myomo, Inc. COMPENSATION RECOVERY POLICY Adopted as of September 13, 2023 Myomo, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and former Executive Officers

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

Insider Trading Policy

Exhibit 19.1 MYOMO, INC. AMENDED AND RESTATED Insider Trading POLICY Myomo, Inc. (the “Company”) has adopted the following policy and procedures for securities trading by Company directors and employees (our “Insider Trading Policy”). Our Insider Trading Policy is intended to prevent the misuse of material nonpublic information, insider trading in securities, and the severe consequences associated

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

First Amendment to the Loan and Security Agreement, dated February 18, 2025, between the Company and Silicon Valley Bank, a division of First-Citizens Bank & Trust Compan

Exhibit 10.1 FIRST Amendment to Loan and security agreement This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 18th day of February, 2025 by and between Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”) and MYOMO, INC., a Delaware corporation (“Borrower”), whose address is 137 Portland St., 4th Floor, Boston, MA 02114. Recitals

Joint Filing Agreement

EX-99.A BD-DIR-RESOL 2 exAmyo14-02-2024.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salagon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Direct

Underwriting Agreement, dated as of December 4, 2024, by and between Myomo, Inc. and Craig-Hallum Capital Group LLC.

Exhibit 1.1 MYOMO, INC. 3,000,000 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement December 4, 2024 CRAIG-HALLUM CAPITAL GROUP LLC 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Myomo, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Craig-Hallum Capital Group LLC, in its capacity as underwriter (the “Underw

MYOMO, INC. PRICES $15.0 MILLION PUBLIC OFFERING OF COMMON STOCK

Exhibit 99.2 MYOMO, INC. PRICES $15.0 MILLION PUBLIC OFFERING OF COMMON STOCK BOSTON, December 5, 2024 – Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has priced an underwritten public offering of 3,000,000 shares of its common stoc

3,000,000 Shares of Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281311 PROSPECTUS SUPPLEMENT (to Prospectus dated August 28, 2024) 3,000,000 Shares of Common Stock We are offering 3,000,000 shares of our common stock by this prospectus supplement and the accompanying prospectus, at a public offering price of $5.00 per share. Our common stock is listed on NYSE American under the symbol “MYO

MYOMO, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Exhibit 99.1 MYOMO, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK BOSTON, December 4, 2024 – Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it intends to offer and sell shares of its common stock in an underwritten public offe

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 Myomo, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38109 47-0944526 (State or other jurisdiction of incorporation) (Commission File Numbe

Subject to Completion, dated December 4, 2024

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281311 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Myomo Reports Record Third Quarter Financial and Operating Results $9.2 million in revenue, raises full-year revenue guidance 225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end 645 additions to the pipeline result in 1,

Exhibit 99.1 Myomo Reports Record Third Quarter Financial and Operating Results $9.2 million in revenue, raises full-year revenue guidance 225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end 645 additions to the pipeline result in 1,263 patients in the pipeline as of September 30, 2024 BOSTON (November 6, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MY

Joint Filing Agreement

EX-99.A BD-DIR-RESOL 2 exAmyo14-02-2024.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salagon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Direct

MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment

SC 13G/A 1 rosalindmyo13ga6sep20.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 6) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the

Myomo, Inc. 137 Portland St., 4th Floor Boston, MA 02114

Myomo, Inc. 137 Portland St., 4th Floor Boston, MA 02114 VIA EDGAR August 26, 2024 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Myomo, Inc. Acceleration Request for Registration Statement on Form S-3 Filed August 6, 2024, as amended on August 26, 2024 File No. 333-281311 Ladies and Gentlemen: Pursuant to Rule 461 under the Se

As filed with the Securities and Exchange Commission on August 26, 2024

Table of Contents As filed with the Securities and Exchange Commission on August 26, 2024 Registration No.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

Lease Agreement, dated August 9, 2024, by and between the Registrant and NDB Property Owner 1. L.P.

Exhibit 10.1 BLUE SKY CENTER OFFICE LEASE NDB PROPERTY OWNER 1, L.P. (AS LANDLORD) AND MYOMO, INC. (AS TENANT) FOR PREMISES AT 45 BLUE SKY DRIVE BURLINGTON, MASSACHUSETTS TABLE OF CONTENTS TABLE OF CONTENTS i ARTICLE 1 REFERENCE DATA 1 1.1 Subject Referred To 1 1.2 Exhibits 4 ARTICLE 2 PREMISES AND TERM 5 2.1 Premises 5 2.2 TERM 6 2.3 Extension Option 6 ARTICLE 3 IMPROVEMENTS 9 3.1 Performance of

LETTER

August 12, 2024 Paul R. Gudonis Chief Executive Officer MYOMO, INC. 137 Portland St., 4th Floor Boston, Massachusetts 02114 Re: MYOMO, INC. Registration Statement on Form S-3 Filed August 6, 2024 File No. 333-281311 Dear Paul R. Gudonis: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accelera

As filed with the Securities and Exchange Commission on August 6, 2024

Table of Contents As filed with the Securities and Exchange Commission on August 6, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Myomo, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

Myomo Reports Second Quarter 2024 Financial Results Record revenue of $7.5 million Record 213 MyoPro® authorizations and orders Record 550 additions to the pipeline, with 1,179 patients in the pipeline at quarter-end

Exhibit 99.1 Myomo Reports Second Quarter 2024 Financial Results Record revenue of $7.5 million Record 213 MyoPro® authorizations and orders Record 550 additions to the pipeline, with 1,179 patients in the pipeline at quarter-end BOSTON (August 6, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those s

As filed with the U.S. Securities and Exchange Commission on August 6, 2024

As filed with the U.S. Securities and Exchange Commission on August 6, 2024 Registration No. 333-     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MYOMO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-0944526 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Emp

Filing Fee Table.

Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Myomo, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 par value per

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Myomo, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Car

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO,

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Em

Loan and Security Agreement, dated July 11, 2024, between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company

Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, a division of First-Citizens Bank & Trust Company (“Bank”), and MYOMO, INC., a Delaware corporation (“Borrower”). The parties agree as follows: 1  LOAN AND TERMS OF PAYMENT 1.1 Revolving Line. (a)  Availability. Subject to the terms and conditi

Joint Filing Agreement

Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc.

Joint Filing Agreement

Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc.

MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 5) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) June 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 5) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) June 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

Myomo Reports Preliminary Second Quarter 2024 Revenues and Operating Metrics Expects record quarterly revenues of $7.2 million to $7.4 million, an increase of 92% to 97% sequentially Generates record pipeline additions, and authorizations and orders

Exhibit 99.1 Myomo Reports Preliminary Second Quarter 2024 Revenues and Operating Metrics Expects record quarterly revenues of $7.2 million to $7.4 million, an increase of 92% to 97% sequentially Generates record pipeline additions, and authorizations and orders BOSTON (July 8, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers incr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 Myomo, Inc. (Exact N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

MYO / Myomo, Inc. / Triple Gate Partners, LP - AMENDMENT NO. 2 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Myomo, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 62857J102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi

Exhibit 1.01 — Conflict Minerals Report of Myomo, Inc. for the year ended December 31, 2023, as required by Items 1.01 and 1.02 of this Form SD.

Exhibit 1.01 Conflict Minerals Report of Myomo, Inc. For the Year Ended December 31, 2023 Introduction This is the Conflict Minerals Report (the “CMR”) of Myomo, Inc. (the “Company,” “we” or “us” or “our”) for the reporting period from January 1, 2023 to December 31, 2023 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule req

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Myomo, Inc. (Exact name of the registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Myomo, Inc. (Exact name of the registrant as specified in its charter) Delaware 001-38109 47-0944526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 137 Portland St., 4th Floor, Boston, Massachusetts 02114 (Address of principal exec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Empl

Myomo Reports First Quarter 2024 Financial Results Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over t

Exhibit 99.1 Myomo Reports First Quarter 2024 Financial Results Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 8, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or

Myomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS Fees Claims Remitted for Payment by All Four Billing Regions Orthotics and Prosthetics Providers Beginning to Receive Reimbursement at

Exhibit 99.1 Myomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS Fees Claims Remitted for Payment by All Four Billing Regions Orthotics and Prosthetics Providers Beginning to Receive Reimbursement at Published Rates BOSTON (May 6, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

ARS

2023AnnualReportpg.1 ToMyFellowShareholders: It’sanewworldforstrokesurvivorsandotherswithupperextremityimpairmentcausedby neurologicalinjuriesordisease.AsofApril1,2024,theCentersforMedicare&Medicaid Services(CMS)publishedthefeeschedulefortheMyoPro®poweredarmbraces,andMedicare PartB(standardMedicarefee-for-service)patientsareeligibleforourdevicesforthefirsttime. MedicareCoverageandPaymentScheduleEs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment

SC 13G/A 1 rosalindmyo13ga4apr25.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 4) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) March 31, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul

Joint Filing Agreement

EX-99.A BD-DIR-RESOL 2 exAmyo14-02-2024.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salagon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Direct

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Myomo Appoints Heather Getz to its Board of Directors

Exhibit 99.1 Myomo Appoints Heather Getz to its Board of Directors BOSTON (March 28, 2024) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit commit

List of Subsidiaries

Exhibit 21.1 Myomo, Inc. List of Subsidiaries Subsidiary Legal Name Employer ID Number % Owned State/Country Incorporated Myomo Europe GmbH NA 100% Germany

Employment Agreement dated December 13, 2023 by and between the Company and Paul R Gudonis

Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is between Myomo, Inc. (“Myomo” or the “Company”), a Delaware corporation with offices at 137 Portland St., 4th Floor, Boston, MA 02114, and Paul R. Gudonis, an individual (“Executive”) residing at 56 Masconomo St., Manchester, MA 01944, is made as of the date of the last signature on the signature pages hereto and upon

m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Compensation Recovery Policy

Exhibit 97.1 Myomo, Inc. COMPENSATION RECOVERY POLICY Adopted as of September 13, 2023 Myomo, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from current and former Executive Officers

Amendment to Employment Agreement dated February 21, 2024 by and between Myomo, Inc. and Micah Mitchell.

Exhibit 10.10 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (the “Amendment”) is made as of February 21, 2024, and amends the Employment Agreement dated April 22, 2021 between Myomo, a Delaware corporation (the “Company”), and Micah Mitchell (the “Executive”) (such Agreement, the “Employment Agreement”). NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, a

Myomo Reports Fourth Quarter and Full Year 2023 Financial Results Q4 total revenue of $4.8 million, up 18% over the prior year Addition of Medicare Part B patients to backlog results in record 183 MyoPro orders and insurance authorizations received i

Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2023 Financial Results Q4 total revenue of $4.8 million, up 18% over the prior year Addition of Medicare Part B patients to backlog results in record 183 MyoPro orders and insurance authorizations received in Q4, up 87% over the prior year Record backlog of 230 patients as of December 31, 2023 Introduces 2024 first quarter and full year guida

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em

CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro® Fees for codes L8701 and L8702 are effective as of April 1, 2024

Exhibit 99.1 CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro® Fees for codes L8701 and L8702 are effective as of April 1, 2024 BOSTON (March 1, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that on

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2024 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Amended Employment Agreement by and between Myomo, Inc. and David Henry dated February 21, 2024.

Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (the “Amendment”) is made as of February 21, 2024 , and amends the Employment Agreement dated April 22, 2021 between Myomo, a Delaware corporation (the “Company”), and David Henry (the “Executive”) (such Agreement, the “Employment Agreement”). NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, and

Amended and Restated Change in Control and Severance Agreement by and between Myomo, Inc. and Harry Kovelman dated February 21, 2024.

Exhibit 10.2 AMENDED AND RESTATED CHANGE OF CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change of Control and Severance Agreement (“Agreement”) is made as of February 21, 2024, and amends, restates and supersedes the Change of Control and Severance Agreement dated September 24th 2020, between Myomo , a Delaware corporation (the “Company”), and Harry Kovelman (the “Executive”). The “T

MYO / Myomo, Inc. / PACKER PAUL Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Myomo, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 62857J102 (CUSIP Number) December 31, 2023 (Date of Event which requires Filing of this Statement

Joint Filing Agreement

EX-99.A BD-DIR-RESOL 2 exAmyo13ga14-02-2024.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salagon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Di

MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 3) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t

MYO / Myomo, Inc. / Rosalind Advisors, Inc. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 3) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t

Joint Filing Agreement

EX-99.A BD-DIR-RESOL 2 exAmyo13ga14-02-2024.htm Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salagon Title: President Rosalind Master Fund L.P. By: Name: Mike McDonald Title: Di

MYO / Myomo, Inc. / HIRSCHMAN ORIN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) January 16, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

Form of Securities Purchase Agreement between Myomo, Inc, and investors identified on the signatures thereto dated January 16, 2024. (Incorporated by reference to Exhibit 10.1 in the Registrant's Form 8-K filed on January 17, 2024)

EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 16, 2024, between Myomo, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 Myomo, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Placement Agency Agreement by and between Myomo, Inc. and AGP Alliance Global Partners dated January 16, 2024. (Incorporated by reference to Exhibit 10.2 contained in the Registrant's Form 8-K filed on January 17, 2024)

EX-10.2 Exhibit 10.2 January 16, 2024 Myomo, Inc. 137 Portland St., 4th Floor Boston, Massachusetts 02114 Attn: President and Chief Executive Officer Dear Mr. Gudonis: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Myomo, Inc., a company incorporated under the laws of the State of Delaware (the “Compa

Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market

EX-99.2 Exhibit 99.2 Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market BOSTON (January 17, 2024) — Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has entered into securities p

Myomo Reports Preliminary Fourth Quarter Revenue and Backlog

EX-99.1 Exhibit 99.1 Myomo Reports Preliminary Fourth Quarter Revenue and Backlog BOSTON (January 17, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary revenue and operating metrics for the fourth quarter of

Form of pre-funded warrant. (Incorporated by reference to Exhibit 4.1 in the Registrant's Form 8-K filed on January 17, 2024)

EX-4.1 Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK MYOMO, INC. Warrant Shares: Initial Exercise Date: January [•], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at a

1,354,218 Shares of Common Stock 224,730 Pre-Funded Warrants 224,730 Shares of Common Stock Underlying Pre-Funded Warrants

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 PROSPECTUS SUPPLEMENT (to Prospectus dated May 25, 2021) 1,354,218 Shares of Common Stock 224,730 Pre-Funded Warrants 224,730 Shares of Common Stock Underlying Pre-Funded Warrants We are offering 1,354,218 shares of our common stock by this prospectus supplement and the accompanying prospectus. We are also offerin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOM

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments

Exhibit 99.1 Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients Conference call begins at 4:30 p.m. Eastern time today BOSTON (November 7, 2023) – Myomo, Inc. (NYSE Am

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numb

CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro® for Review at the Upcoming HCPCS Public Meeting Public Meeting Scheduled for November 29, 2023

Exhibit 99.1 CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro® for Review at the Upcoming HCPCS Public Meeting Public Meeting Scheduled for November 29, 2023 BOSTON (November 6, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb

Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category Standard Medicare Part B Patients now have access to the MyoPro, which will be reimbursed on a lump sum basis

Exhibit 99.1 Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category Standard Medicare Part B Patients now have access to the MyoPro, which will be reimbursed on a lump sum basis BOSTON (November 2, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering fro

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numb

MYO / Myomo Inc / HIRSCHMAN ORIN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) August 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

MYO / Myomo Inc / Triple Gate Partners, LP - AMENDMENT NO. 1 Passive Investment

SC 13G/A 1 x831230sc13ga1.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Myomo, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 62857J102 (CUSIP Number) August 24, 2023 (Date of Event which Requires Filing of this Statement) Check the appropria

Placement Agency Agreement by and between Myomo, Inc. and AGP Alliance Global Partners dated August 24, 2023. (Incorporated by reference to Exhibit 10.1 contained in the Registrant's Form 8-K filed on August 28, 2023)

Exhibit 10.1 August 24, 2023 Myomo, Inc. 137 Portland St., 4th Floor Boston, Massachusetts 02114 Attn: President and Chief Executive Officer Dear Mr. Gudonis: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Myomo, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), tha

5,413,334 Shares of Common Stock 1,920,000 Pre-Funded Warrants 1,920,000 Shares of Common Stock Underlying Pre-Funded Warrants

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 PROSPECTUS SUPPLEMENT (to Prospectus dated May 25, 2021) 5,413,334 Shares of Common Stock 1,920,000 Pre-Funded Warrants 1,920,000 Shares of Common Stock Underlying Pre-Funded Warrants We are offering on a “reasonable best efforts” basis 5,413,334 shares of our common stock at a public offering price of $0.60 per s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 Myomo, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Joint Filing Agreement

Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial otnership of shares of Common Stock of Myomo, Inc.

MYO / Myomo Inc / Rosalind Advisors, Inc. - MYOMO, INC. 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J271 (CUSIP Number) August 25, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule puwsuant to which this Schedule is

Form of Pre-Funded Warrant

Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK MYOMO, INC. Warrant Shares: Initial Exercise Date: August 29, 2023 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number

Myomo Receives Medicare Part B Reimbursement for First MyoPro® Claims Appropriate payment amounts received on two MyoPro claims; Additional claims are under review while CMS rulemaking to re-classify the MyoPro to the brace benefit category progresse

Exhibit 99.1 Myomo Receives Medicare Part B Reimbursement for First MyoPro® Claims Appropriate payment amounts received on two MyoPro claims; Additional claims are under review while CMS rulemaking to re-classify the MyoPro to the brace benefit category progresses BOSTON (August 24, 2023) ─ Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers

A.G.P. The date of this prospectus supplement is August 24, 2023.

424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 25, 2021) This prospectus supplement supplements and amends certain information contained in the prospectus supplement dated August 2, 2022 to the prospectus supplement dated June 25, 2021 to the prospectus dated May 25, 2021 (collectively, the “ATM Prospectus”), relating to the offer

Subject to Completion, dated August 24, 2023

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these secu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Myomo, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, IN

Myomo Reports Second Quarter 2023 Financial Results Featuring Year Over Year Growth in Revenue and Operating Metrics Q2 revenue of $6.0 million, including license revenue Nearly 1,000 prospective MyoPro® candidates with known payers in the patient pi

Exhibit 99.1 Myomo Reports Second Quarter 2023 Financial Results Featuring Year Over Year Growth in Revenue and Operating Metrics Q2 revenue of $6.0 million, including license revenue Nearly 1,000 prospective MyoPro® candidates with known payers in the patient pipeline Begins to build Medicare Part B patient pipeline following publication of proposed rule by the Centers for Medicare and Medicaid S

Amendment No. 2 to the Myomo, Inc. 2018 Stock Option and Incentive Plan (incorporated by reference to Exhibit 99.3 contained in the Registrant’s Form S-8 filed on June 28, 2023).

EX-99.3 Exhibit 99.3 SECOND AMENDMENT TO THE MYOMO, INC. 2018 STOCK OPTION AND INCENTIVE PLAN This Second Amendment (this “Amendment”) to the Myomo, Inc. 2018 Stock Option and Incentive Plan, as amended (the “Plan”), of Myomo, Inc. (the “Company”) is effective as of the date of approval by the Company’s stockholders (the “Effective Date”). Capitalized terms used herein and not otherwise defined sh

Power of Attorney (see page II-1 of this Registration Statement on Form S-8).

S-8 As filed with the U.S. Securities and Exchange Commission on June 28, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MYOMO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-0944526 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Empl

Filing Fee Table.

EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Myomo, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Myomo Reports First Quarter 2023 Financial Results Featuring 20% Year Over Year Increase in Product Revenue Implementation of virtual waiting room technology enabled a record 438 patients added to the pipeline, up 54% over Q1 2022 Advertising efficie

Exhibit 99.1 Myomo Reports First Quarter 2023 Financial Results Featuring 20% Year Over Year Increase in Product Revenue Implementation of virtual waiting room technology enabled a record 438 patients added to the pipeline, up 54% over Q1 2022 Advertising efficiencies resulted in cost per pipeline add of $1,579, down 50% sequentially Conference call begins at 4:30 p.m. Eastern time today BOSTON (M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Myomo, Inc. (Exact N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp

ARS

2022AnnualReportToMyFellowStockholders: I’mveryproudtobewritingyouasMyomomarksadecadeofrevenuegrowthbyhelpinga growingnumberofpatientstoimprovetheirliveswithaMyoPro®poweredarmbrace.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Myomo Receives Technology License Fee Payment from China Joint Venture Company Payment of $1.7 million permits the start of activities to manufacture and sell the MyoPro® in China

Exhibit 99.1 Myomo Receives Technology License Fee Payment from China Joint Venture Company Payment of $1.7 million permits the start of activities to manufacture and sell the MyoPro® in China BOSTON (April 10, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 06, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number)

MYO / Myomo Inc / Strategic Risk, LLC. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Myomo , Inc. U n d e r t h e S e c u r i t i e s E x c h a n g e A c t o f 1 9 3 4 ( A m e n d m e n t N o .. ) * ( N a m e o f I s s u e r ) Common Stock ..001 Par Value 62857J102 ( T i t l e o f C l a s s o f S e c u r i t i e s ) ( C U S I P N u m b e r ) Strategic Risk LLC 228 Park Ave S. PMB 828333 NY, NY 100

m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

List of Subsidiaries

Exhibit 21.1 Myomo, Inc. List of Subsidiaries Subsidiary Legal Name Employer ID Number % Owned State/Country Incorporated Myomo Europe GmbH NA 100% Germany

Myomo Reports Fourth Quarter and Full Year 2022 Financial Results Fourth quarter revenue was $4.0 million, up 2% sequentially 387 patients added to the pipeline in fourth quarter, up 75% compared with Q4 2021 Conference call begins at 10:00 a.m. East

Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2022 Financial Results Fourth quarter revenue was $4.0 million, up 2% sequentially 387 patients added to the pipeline in fourth quarter, up 75% compared with Q4 2021 Conference call begins at 10:00 a.m. Eastern time today BOSTON (March 13, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

MYO / Myomo Inc / Hewlett Fund LP - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) MYOMO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 62857J201 (CUSIP Number) February 14, 2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule purs

MYO / Myomo Inc / Must Asset Management Inc. - SCHEDULE 13G AMENDMENT NO. 2 Passive Investment

SCHEDULE 13G AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MYOMO, INC. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 62857J201 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

Exhibit 99.1 Myomo Appoints Yitzchak Jacobovitz to its Board of Directors BOSTON (January 30, 2023) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective Jan

MYO / Myomo Inc / PACKER PAUL Passive Investment

SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Myomo, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 62857J102 (CUSIP Number) January 12, 2023 (Date of Event which requires Fil

MYO / Myomo Inc / HIRSCHMAN ORIN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) January 12, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

MYO / Myomo Inc / Hewlett Fund LP - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) MYOMO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 62857J201 (CUSIP Number) January 17, 2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule pursuant

Form of Securities Purchase Agreement between Myomo, Inc. and investors identified on the signatures thereto dated January 13, 2023. (Incorporated by reference to Exhibit 10.1 in the Registrant's From 8-K filed on January 13, 2023).

EX-10.1 3 myo-ex101.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 11, 2023, between Myomo, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to th

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

13,169,074 Shares of Common Stock 6,830,926 Pre-Funded Warrants 6,830,926 Shares of Common Stock Underlying Pre-Funded Warrants

424B4 1 d364362d424b4.htm 424B4 Table of Contents As Filed Pursuant to Rule 424(b)(4) Registration No. 333-268705 Registration No. 333-269189 PROSPECTUS 13,169,074 Shares of Common Stock 6,830,926 Pre-Funded Warrants 6,830,926 Shares of Common Stock Underlying Pre-Funded Warrants We are offering on a “reasonable best efforts” basis 13,169,074 shares of common stock at a public offering price of $0

Placement Agency Agreement by and between Myomo, Inc. and AGP Alliance Global Partners dated January 11, 2023. (Incorporated by reference to Exhibit 10.2 contained in the Registrant's Form 8-K filed on January 13, 2023).

Exhibit 10.2 January 11, 2023 Myomo, Inc. 137 Portland St., 4th Floor Boston, Massachusetts 02114 Attn: President and Chief Executive Officer Dear Mr. Gudonis: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Myomo, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), th

Form of pre-funded warrant. (Incorporated by reference to Exhibit 4.1 in the Registrant's Form 8-K filed on January 13, 2022)

EX-4.1 2 myo-ex41.htm EX-4.1 Exhibit 4.1 Pre-Funded WARRANT To purchase Shares of Common Stock MYOMO, INC. Warrant Shares: Initial Exercise Date: January 17, 2023 THIS Pre-Funded WARRANT to Purchase Shares of Common Stock (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions herein

As filed with the Securities and Exchange Commission on January 10, 2023.

S-1/A Table of Contents As filed with the Securities and Exchange Commission on January 10, 2023.

As filed with the Securities and Exchange Commission on January 11, 2023.

S-1MEF As filed with the Securities and Exchange Commission on January 11, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MYOMO, INC. (Exact name of Registrant as specified in its charter) Delaware 3842 47-0944526 (State or other jurisdiction of incorporation or organization) (Prim

Filing Fee Table.

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Myomo, Inc.

As filed with the Securities and Exchange Commission on January 10, 2023.

S-1/A Table of Contents As filed with the Securities and Exchange Commission on January 10, 2023.

Form of Securities Purchase Agreement in connection with this offering

Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January [], 2023, between Myomo, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fort

Form of Pre-Funded Warrant

Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK MYOMO, INC. Warrant Shares: Initial Exercise Date: January [ ], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time

Myomo Announces Initiative to Reduce Cash Burn Undertakes a reduction in force to enhance efficiency in its direct billing channel

Exhibit 99.1 Myomo Announces Initiative to Reduce Cash Burn Undertakes a reduction in force to enhance efficiency in its direct billing channel BOSTON, January 10, 2023 - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced a redu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numbe

As filed with the Securities and Exchange Commission on January 4, 2023.

S-1/A Table of Contents As filed with the Securities and Exchange Commission on January 4, 2023.

Form of Securities Purchase Agreement in connection with this offering

EX-10.20 Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January [], 2023, between Myomo, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Myomo, Inc.

Form of Placement Agent Agreement by and between Myomo, Inc. and A.G.P./Alliance Global Partners

EX-1.1 Exhibit 1.1 January [], 2023 Myomo, Inc. 137 Portland St., 4th Floor Boston, Massachusetts 02114 Attn: President and Chief Executive Officer Dear Mr. Gudonis: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners, as placement agent (the “Placement Agent”), and Myomo, Inc., a company incorporated under the laws of the State of Delaware (the “Company

Form of Pre-Funded Warrant

EX-4.1 Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK MYOMO, INC. Warrant Shares: Initial Exercise Date: January [], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Myomo, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 07, 2022 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Numb

As filed with the Securities and Exchange Commission on December 7, 2022.

S-1 Table of Contents As filed with the Securities and Exchange Commission on December 7, 2022.

MYO / Myomo Inc / HIRSCHMAN ORIN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) November 18, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog Third quarter revenue of $4.0 million, up 8% sequentially 130 authorizations and orders results in a record-high backlog of 184 units Con

Exhibit 99.1 Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog Third quarter revenue of $4.0 million, up 8% sequentially 130 authorizations and orders results in a record-high backlog of 184 units Conference call begins at 4:30 p.m. Eastern time today BOSTON (November 10, 2022) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOM

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Num

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

s UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO,

Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions Second quarter revenue of $3.7 million up 18% over prior year Cost per pipeline addition cut in half over the last six months Conference call begins a

Exhibit 99.1 Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions Second quarter revenue of $3.7 million up 18% over prior year Cost per pipeline addition cut in half over the last six months Conference call begins at 4:30 p.m. Eastern time today BOSTON (August 3, 2022) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Company?), a wearable medical

Up to $300,000 Common Stock

424B5 1 d384578d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 SUPPLEMENT TO PROSPECTUS SUPPLEMENT DATED JUNE 25, 2021 (To Prospectus Dated May 25, 2021) Up to $300,000 Common Stock This prospectus supplement, or this supplement, supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our prospectus

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E

Up to $5.0 Million of Shares of Common Stock 50,000 Shares of Common Stock

424B5 1 d382569d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256159 PROSPECTUS SUPPLEMENT (to Prospectus dated May 25, 2021) Up to $5.0 Million of Shares of Common Stock 50,000 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to $5,000,000 in shares of our common stock, par value $0.0001 per share (the “Common Stock

Common Stock Purchase Agreement dated August 2, 2022 by and between Myomo, Inc., and Keystone Capital Partners, LLC. (incorporated by reference to Exhibit 1.1 contained in the Registrant’s Form 8-K dated August 2, 2022)

EX-1.1 2 d384616dex11.htm EX-1.1 Exhibit 1.1 COMMON STOCK PURCHASE AGREEMENT DATED AS OF AUGUST 2, 2022 BY AND BETWEEN MYOMO, INC. AND KEYSTONE CAPITAL PARTNERS, LLC TABLE OF CONTENTS ARTICLE I PURCHASE AND SALE OF COMMON STOCK 1 Section 1.1 Purchase and Sale of Stock 1 Section 1.2 Commencement Date; Settlement Dates 2 Section 1.3 Current Report; Prospectus Supplement 2 ARTICLE II PURCHASE TERMS 3

Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions

EX-99.1 2 myo-ex991.htm EX-99.1 Exhibit 99.1 Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions BOSTON (July 7, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenu

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 07, 2022 MYOMO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number)

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp

MYO / Myomo Inc / Must Asset Management Inc. - SCHEDULE 13G AMENDMENT NO. 1 Passive Investment

SCHEDULE 13G AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MYOMO, INC. (Name of Issuer) Common Stock, par value of $0.0001 per share (Title of Class of Securities) 62857J201 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate

Myomo Reports First Quarter 2022 Financial Results Revenue of $3.9 million up 66% over prior year, product revenue of $2.9 million up 23% Pipeline of 924 MyoPro candidates up 14% over fourth quarter of 2021 Conference call begins at 4:30 p.m. Eastern

Exhibit 99.1 Myomo Reports First Quarter 2022 Financial Results Revenue of $3.9 million up 66% over prior year, product revenue of $2.9 million up 23% Pipeline of 924 MyoPro candidates up 14% over fourth quarter of 2021 Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 11, 2022) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Company?), a wearable medical robotics company that

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, I

Schedule 14A

DEF 14A 1 d288247ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee

Exhibit 99.1 Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee BOSTON (April 4, 2022) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Company?), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, provides an update on the status of its joint venture (

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em

Amended and Restated Equity Joint Venture Contract by and between Myomo, Inc., Anhui Ryzur Medical Equipment Manufacturing Co. Ltd., Wuxi Chinaleaf Rehabilitation Industry Equity Investment Fund (Limited Partnership) and Beijing Ryzur Medical Investment Company Ltd., dated December 29, 2021 (incorporated by reference to Exhibit 10.27 contained in the Registrant’s Annual Report on Form 10-K dated March 11, 2022).

Exhibit 10.27 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDED AND RESTATED EQUITY JOINT VENTURE CONTRACT among ANHUI RYZUR MEDICAL EQUIPMENT MANUFACTURING CO., LTD. (??????????????) WUXI CHINALEAF REHABILITATION

Technology License Agreement by and between Myomo, Inc, and Jiangxi Myomo Medical Assistive Appliance Co., Ltd., dated December 29, 2021 (incorporated by reference to Exhibit 10.28 contained in the Registrant’s Annual Report on Form 10-K dated March 11, 2022).

Exhibit 10.28 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. TECHNOLOGY LICENSE AGREEMENT This TECHNOLOGY LICENSE AGREEMENT (this ?License Agreement?) dated as of December 29, 2021 (the ?Signing Date?), is entered into

Trademark License Agreement by and between Myomo, Inc. and Jiangxi Myomo Medical Assistive Appliance Co., Ltd., dated December 29, 2021 (incorporated by reference to Exhibit 10.29 contained in the Registrant’s Annual Report on Form 10-K dated March 11, 2022).

Exhibit 10.29 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. TRADEMARK LICENSE AGREEMENT This TRADEMARK LICENSE AGREEMENT (this ?Trademark License Agreement?) dated as of December 29, 2021, is entered into by and betwe

Secured Promissory Note from the Company to Iliad Research and Trading, L.P. dated October 22, 2019 (incorporated by reference to Exhibit 10.2 contained in the Registrant’s Form 8-K filed on October 23, 2019)

Exhibit 21.1 Myomo, Inc. List of Subsidiaries Subsidiary Legal Name Employer ID Number % Owned State/Country Incorporated Myomo Europe GmbH NA 100% Germany

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3

Myomo Reports Fourth Quarter and Full Year 2021 Financial Results Fourth quarter revenue of $4.0 million up 6% over prior year, full year revenue of $13.9 million up 83% over 2020 Fourth quarter gross margin of 77.4% up 400 basis points over prior ye

Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2021 Financial Results Fourth quarter revenue of $4.0 million up 6% over prior year, full year revenue of $13.9 million up 83% over 2020 Fourth quarter gross margin of 77.4% up 400 basis points over prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (March 9, 2022) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Comp

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em

MYO / Myomo Inc / HIRSCHMAN ORIN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

MYO / Myomo Inc / Rosalind Advisors, Inc. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Myomo, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 62857J201 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

Joint Filing Agreement

Exhibit A Joint Filing Agreement The undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stock of Myomo, Inc.

Myomo Provides Update on MyoPro® Insurance Reimbursement

EX-99.1 Exhibit 99.1 Myomo Provides Update on MyoPro® Insurance Reimbursement BOSTON, Mass (January 10, 2022) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today provided an update on reimbursement for its MyoPro device by a large privat

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOM

Myomo Third Quarter 2021 Financial Results Feature Record Revenue Revenue of $4.4 million up 128% over prior year, up 159% year-to-date Gross margin of 75% up 1,900 basis points over prior year Backlog increased to 177 units Conference call begins at

Exhibit 99.1 Myomo Third Quarter 2021 Financial Results Feature Record Revenue Revenue of $4.4 million up 128% over prior year, up 159% year-to-date Gross margin of 75% up 1,900 basis points over prior year Backlog increased to 177 units Conference call begins at 4:30 p.m. Eastern time today BOSTON, Mass. (November 10, 2021) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Company?), a wearable

Myomo, Inc. Announces Agreements for Exercise of 2020 Investor Warrants

Exhibit 99.1 Myomo, Inc. Announces Agreements for Exercise of 2020 Investor Warrants BOSTON, Mass. (October 15, 2021) ? Myomo, Inc. (NYSE American: MYO) (?Myomo? or the ?Company?), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced it has entered into agreements with certain of its holder

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Form of Letter Agreement

Exhibit 10.1 October 14, 2021 [Name and address of warrant holder] Re: Exercise Price Reset Offer of Common Stock Purchase Warrants To Whom It May Concern: Myomo, Inc. (the ?Company?) is pleased to offer to you the opportunity to reprice the Exercise Price of all of the Common Stock purchase warrants of the Company (the ?Warrants?) currently held by you (the ?Holder?) and as set forth on your sign

MYO / Myomo Inc / HIRSCHMAN ORIN Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYOMO, INC. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 62857J102 (CUSIP Number) September 20, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 Myomo, Inc. (Exact Name of Company as Specified in Charter) Delaware 001-38109 47-0944526 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Amendment No. 1 to Fabrication and Services Agreement, dated October 1, 2021, between the Company and Geauga Rehabilitation Engineering, Inc.

Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, IN